Market Place
Sourcing Support
Pfizer’s Velsipity faces stiff competition in UC market: reports
04 Apr 2024 //
FIERCE PHARMA
Everest Medicines Announces Acceptance of VELSIPITY® NDA in Macau
10 Mar 2024 //
PR NEWSWIRE
Pfizer inflammatory bowel disease drug wins EU approval
20 Feb 2024 //
PRESS RELEASE
Pfizer`s Velsipity (etrasimod) Receives Approval in Europe
16 Feb 2024 //
EMA
Everest Medicines` Licensing Partner Pfizer Announces FDA Approves Etrasimod
15 Oct 2023 //
PR NEWSWIRE
Everest Medicines Announces Completion in Ph 3 Trial of Etrasimod in Asia
16 May 2023 //
PR NEWSWIRE
FDA and EMA accept Pfizer’s regulatory submissions for ulcerative colitis drug
22 Dec 2022 //
ENDPTS
Pfizer spells out PhIII data on $6.7B Arena drug
25 May 2022 //
ENDPTS
Everest Medicines` Partner Pfizer Presents ELEVATE Pivotal Findings of Etrasimod
24 May 2022 //
PRNEWSWIRE
Pfizer’s bowel disease drug succeeds in second late-stage study
03 Apr 2022 //
EXPRESS PHARMA
Pfizer Announces Positive Top-line Results from Phase 3 Trial of Etrasimod in UC
29 Mar 2022 //
BUSINESSWIRE
Pfizer claims study success for drug key to Arena buyout
24 Mar 2022 //
BIOPHARMADIVE
Pfizer bets on Arena`s promising bowel disease treatment in $6.7 bln deal
14 Dec 2021 //
REUTERS
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A
19 Nov 2021 //
BUSINESSWIRE
Arena`s lead drug misses on PhII in AD, thwacking stock, but companyPhase III
10 Nov 2020 //
ENDPTS
Arena Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD)
09 Nov 2020 //
PRNEWSWIRE
Arena Reports Third Quarter Financial Results with Strong Cash Position
09 Nov 2020 //
PRNEWSWIRE
Arena Pharmaceuticalsbegins in ELEVATE UC 12 Global Phase 3
16 Sep 2020 //
PRNEWSWIRE
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE Trial
16 Sep 2020 //
PRNEWSWIRE
Arena Completes Full Enrollment of Etrasimod Ph2 ADVISE Trial
26 May 2020 //
PR NEWSWIRE
Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab
08 Mar 2019 //
PR NEWSWIRE
Arena Pharmaceuticals Ph 1 Clinical Data for Ralinepag in PAH at the ESC
29 Aug 2018 //
PR NEWSWIRE
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
20 Mar 2018 //
PR NEWSWIRE
Arena Pharmaceuticals Inks China Deal On 2 Pipeline Candidates
06 Dec 2017 //
SEEKINGALPHA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.